Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Clinical trial NCT05983783 · RECRUITING

Trial details

NCT number: NCT05983783
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Prostate Cancer Hormone Sensitive Prostate Cancer Chemotherapy Effect

Start date: 2023-08-01
Primary completion: 2025-12-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.